TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder Cancer.

Yunkai Qie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.